Applicants have identified a critical skin benefit package that can be used in liquid alcohol sanitizing compositions that provides lower amounts of skin conditioners in combination with a specific ratio of different emollients that provide improved skin health with chronic repeated use. The package also provides improved skin feel with without a tacky residue upon drying.

The invention provides anti-cluster of differentiation 3 (CD3) antibodies and methods of using the same.

The present disclosure relates generally to modulators of Cot (cancer Osaka thyroid) and methods of use and manufacture thereof.

Hidradenitis suppurativa can be treated by administering a pharmaceutical composition that includes a pharmaceutically acceptable carrier and a therapeutically effective amount of an agent that selectively binds IL-1α.

Hidradenitis suppurativa can be treated by administering a pharmaceutical composition that includes a pharmaceutically acceptable carrier and a therapeutically effective amount of an agent that selectively binds IL-1α.

Provided are methods for the use of belvarafenib to treat cancer having at least one mutation selected from a BRAF.sup.V600E mutation, a KRAS.sup.G12V mutation, a KRAS.sup.G12D mutation, a KRAS.sup.G12C mutation, a KRAS.sup.G12R mutation, a KRAS.sup.G13D mutation, a KRAS.sup.Q61H mutation, a NRAS.sup.G12D mutation, a NRAS.sup.G13D mutation, a NRAS.sup.Q61K mutation, a NRAS.sup.Q61L mutation, a NRAS.sup.Q61R mutation, and a NRAS.sup.G12C mutation.

Provided are methods for the use of belvarafenib to treat cancer having at least one mutation selected from a BRAF.sup.V600E mutation, a KRAS.sup.G12V mutation, a KRAS.sup.G12D mutation, a KRAS.sup.G12C mutation, a KRAS.sup.G12R mutation, a KRAS.sup.G13D mutation, a KRAS.sup.Q61H mutation, a NRAS.sup.G12D mutation, a NRAS.sup.G13D mutation, a NRAS.sup.Q61K mutation, a NRAS.sup.Q61L mutation, a NRAS.sup.Q61R mutation, and a NRAS.sup.G12C mutation.

The present application provides anti-CD93 constructs that bind to CD93 (e.g., anti-CD93 antibodies), nucleic acid molecules encoding an amino acid sequence of the anti-CD93, vectors comprising the nucleic acid molecules, host cells containing the vectors, methods of preparing the anti-CD93 construct, pharmaceutical compositions containing the anti-CD93 construct, and methods of using the anti-CD93 construct or compositions.

The present application provides anti-CD93 constructs that bind to CD93 (e.g., anti-CD93 antibodies), nucleic acid molecules encoding an amino acid sequence of the anti-CD93, vectors comprising the nucleic acid molecules, host cells containing the vectors, methods of preparing the anti-CD93 construct, pharmaceutical compositions containing the anti-CD93 construct, and methods of using the anti-CD93 construct or compositions.

The present invention provides a method for increasing collagen production in a cell and a method for inhibiting cell migration. Further, the present invention provides a pharmaceutical composition comprising lipopeptides, wherein the lipopeptides substantially consist of ETTES lipopeptides, and uses of said pharmaceutical composition. The invention also provides a supramolecular structure comprising lipopeptides, wherein the lipopeptides substantially consist of ETTES lipopeptides, as well as a method for producing said supramolecular structure. The supramolecular structure of the invention may be used in the method for increasing collagen production and/or method for inhibiting cell migration.